Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)
Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)
Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.
Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.
Louis B. Harrison, MD, of the Moffitt Cancer Center, discusses radiation oncology in the context of personalized medicine, multidisciplinary care, new technology and applications, and the mandate to contain costs.
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)
